Heart failure & cardiomyopathies
Personalized Care in Dilated Cardiomyopathy: Rationale and Study Design of the activeDCM Trial
Study context
- Population
- Patients aged 18–75 years with dilated cardiomyopathy (DCM), left ventricular ejection fraction (LVEF) ≤ 50% and New York Heart Association (NYHA) class I–IIIplanned enrolment
- Participants
- 300 patients
- Planned comparison
- Personalized exercise and activity programme
- Primary endpoint
- Increase in peak oxygen uptake (VO2max, mL/kg/min)
- Follow-up
- Baseline to 12 months
Methodological detailsstudy design and rationale, prospective, interventional, 12-month follow-up, Secondary endpoints: adherence to personalized activity programmes, freedom from clinically relevant arrhythmia, unplanned HF hospitalization, changes in NYHA class, quality of life scores, 6 min walk distance, muscular strength, NT-proBNP and high-sensitivity troponin T (hsTnT) levels and cardiac function, Advanced research questions: high-density phenome and omics analysis with digital biomarkers from Apple Watch devices
- Study design and rationale
- Prospective
- Interventional
- 12-month follow-up
- Secondary endpoints: adherence to personalized activity programmes, freedom from clinically relevant arrhythmia, unplanned HF hospitalization, changes in NYHA class, quality of life scores, 6 min walk distance, muscular strength, NT-proBNP and hsTnT levels and cardiac function
- Advanced research questions: high-density phenome and omics analysis with digital biomarkers from Apple Watch devices
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Personalized Care in Dilated Cardiomyopathy: Rationale and Study Design of the activeDCM Trial. ESC Heart Fail. Published 15 July 2024. doi:10.
Summarised from the published abstract; every number is checked against it